资金流向方面，主力资金净流入461.06万元，特大单买入584.22万元，占比5.20%，卖出0.00元，占比 0.00%；大单买入1808.19万元，占比16.08%，卖出1931.35万元，占比17.17%。 分红方面，诚益通A股上市后累计派现8055.38万元。近三年，累计派现3960.21万元。 机构持仓方面，截止2025年9月30日，诚益通十大流通股东中，长城消费增值混合A（200006）位居第 五大流通股东，持股200.00万股，为新进股东。广发聚丰混合A（270005）位居第八大流通股东，持股 133.07万股，为新进股东。广发优势成长股票A（011425）位居第十大流通股东，持股100.79万股，为 新进股东。华夏领先股票（001042）退出十大流通股东之列。 责任编辑：小浪快报 诚益通今年以来股价涨26.38%，近5个交易日涨3.05%，近20日涨6.46%，近60日跌6.81%。 资料显示，北京诚益通控制技术集团股份有限公司位于北京市大兴区生物医药产业基地庆丰西路27号， 成立日期2003年7月22日，上市日期2015年3月19日，公司主营业务涉及提供医药、生物工业自动化控制 系统整体解决 ...

12月19日，诚益通盘中上涨2.09%，截至13:00，报19.05元/股，成交5755.27万元，换手率1.18%，总市 值52.02亿元。 资金流向方面，主力资金净流出99.62万元，大单买入624.62万元，占比10.85%，卖出724.24万元，占比 12.58%。 分红方面，诚益通A股上市后累计派现8055.38万元。近三年，累计派现3960.21万元。 机构持仓方面，截止2025年9月30日，诚益通十大流通股东中，长城消费增值混合A（200006）位居第 五大流通股东，持股200.00万股，为新进股东。广发聚丰混合A（270005）位居第八大流通股东，持股 133.07万股，为新进股东。广发优势成长股票A（011425）位居第十大流通股东，持股100.79万股，为 新进股东。华夏领先股票（001042）退出十大流通股东之列。 责任编辑：小浪快报 资料显示，北京诚益通控制技术集团股份有限公司位于北京市大兴区生物医药产业基地庆丰西路27号， 成立日期2003年7月22日，上市日期2015年3月19日，公司主营业务涉及提供医药、生物工业自动化控制 系统整体解决方案;康复理疗医疗器械的研发、生产和销售业务 ...

Core Viewpoint - The A-share market's industrial hemp concept stocks have shown strong performance, with notable gains in several companies, driven by potential regulatory changes in the U.S. regarding cannabis classification [1][2]. Company Performance - Shunhao Co., Ltd. (002565) reached a limit-up with a 10% increase, total market value at 16.9 billion [2]. - Fuan Pharmaceutical (300194) rose by 4.91%, with a market cap of 5.592 billion [2]. - Blue Sky Technology (300487) increased by 4.85%, total market value at 29.1 billion [2]. - Jinying Co., Ltd. (600232) saw a 4.10% rise, with a market cap of 2.593 billion [2]. - Chengyitong (300430) grew by 3.82%, total market value at 5.117 billion [2]. - Yongji Co., Ltd. (603058) increased by 3.44%, with a market cap of 3.740 billion [2]. - Morning Light Biology (300138) rose by 3.19%, total market value at 6.097 billion [2]. Regulatory Impact - Reports indicate that former President Trump is expected to instruct the government to reclassify cannabis as a lower-risk substance, which could represent a significant shift in U.S. cannabis policy [1][2]. - Discussions have taken place between Trump and industry executives, as well as health officials, regarding this potential reclassification [2]. - The reclassification could facilitate easier buying and selling of cannabis, addressing tax burdens and banking service obstacles for cannabis businesses [2].

Group 1: Industrial Mother Machine Sector - The industrial mother machine sector shows a positive trend with a total index increase of 1.29% to 1754.21 [2] - Key stocks in this sector include: - GuoJi Heavy Industry (601399) with a price of 4.63, up by 9.98% and 42.46% over the past five days [2] - China First Heavy Industries (601106) at 3.42, also up by 9.97% and 13.62% over the last five days [2] - Weihong Co., Ltd. (300508) at 38.12, increasing by 9.29% and 10.05% in five days [2] - Other notable performers include: - Yuhuan CNC (002903) at 24.54, up by 6.70% [2] - Ruineng Technology (603933) at 30.40, with a 5.89% increase [2] Group 2: Brain-Computer Interface Sector - The brain-computer interface sector experienced significant activity, highlighted by the upcoming "Brain Link World, Intelligence Gathering in Shanghai" conference scheduled for December 4-5, 2025 [3] - Key stocks in this sector include: - Dineike (300884) with a price of 16.82, up by 14.34% and 18.09% over the past five days [3] - Nanjing Panda (600775) at 12.55, increasing by 9.99% and 13.78% [3] - Chengyitong (300430) at 18.99, up by 3.94% [3] - Other stocks showing positive movement include: - Beiyikang (920199) at 34.70, up by 3.89% [3] - Innovation Medical (002173) at 22.29, with a 3.05% increase [3]

证券代码：300430 证券简称：诚益通 公告编号：2025-054 北京诚益通控制技术集团股份有限公司 关于为上市公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、融资情况概述 北京诚益通控制技术集团股份有限公司（以下简称"公司"或"诚益通"） 于 2025 年 4 月 23 日召开了第五届董事会第十一次会议，会议审议通过了《关于 预计 2025 年度公司及合并范围内公司申请银行综合授信及项目贷款额度的议案》 《关于预计 2025 年度公司及合并范围内公司担保额度的议案》（公告编号： 2025-020、021），同意公司、子公司及合并报表范围内的子公司、孙公司向银 行及其他金融机构申请合计额度不超过人民币 13.79 亿元的授信等业务，在授权 期限内额度可循环使用，担保总额合计不超过 13.19 亿元。上述议案同时由 2025 年 5 月 15 日召开的 2024 年度股东大会审议通过。 二、融资进展情况 近期，北京诚益通科技有限公司（以下简称"诚益通科技"）与杭州银行股 份有限公司北京分行（以下简称"杭州银行"）签署《杭州银行股份 ...

证券代码：300430 证券简称：诚益通 公告编号：2025-053 北京诚益通控制技术集团股份有限公司 关于为上市公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、融资情况概述 北京诚益通控制技术集团股份有限公司（以下简称"公司"或"诚益通"） 于 2025 年 4 月 23 日召开了第五届董事会第十一次会议，会议审议通过了《关于 预计 2025 年度公司及合并范围内公司申请银行综合授信及项目贷款额度的议案》 《关于预计 2025 年度公司及合并范围内公司担保额度的议案》（公告编号： 2025-020、021），同意公司、子公司及合并报表范围内的子公司、孙公司向银 行及其他金融机构申请合计额度不超过人民币 13.79 亿元的授信等业务，在授权 期限内额度可循环使用，担保总额合计不超过 13.19 亿元。上述议案同时由 2025 年 5 月 15 日召开的 2024 年度股东大会审议通过。 三、被担保人基本情况 1、北京诚益通控制技术集团股份有限公司 公司名称：北京诚益通控制技术集团股份有限公司 成立日期：2003 年 07 月 22 ...

证券代码：300430 证券简称：诚益通 公告编号：2025-052 北京诚益通控制技术集团股份有限公司 | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次解除 | 本次解除 | | 占公司 | 情况 | | 情况 | | | 股东名 | 持股数量 | 持股比例 | 质押前质 | 质押后质 | 占其所持股 | 总股本 | | | 未质押股 | | | 称 | （万股） | | 押股份数 量 | 押股份数 量 | 份比例 | 比例 | 已质押股 | 占已质 | 份限售和 | 占未质押 | | | | | | | | | 份限售和 冻结数量 | 押股份 比例 | 冻结数量 | 股份比例 | | | | | | | | | | | （万股） | | | 立威特 | 5120.98 | 18.75% | 5063 | 3513 | 68.60% | 12.87% | 3513 | 100% | 0 | 0% | | 1013.76 | 3.7 ...

Core Insights - The brain engineering sector is leading the market with a rise of 1.05% [1] Company Performance - Aipeng Medical saw a significant increase of 7.51% [1] - Innovation Medical experienced a rise of 4.41% [1] - Century Huatong increased by 3.41% [1] - Chengyitong, Xiangyu Medical, and Sanbo Brain Science all rose by over 2% [1]

Core Viewpoint - The A-share market is experiencing a surge in brain-computer interface concept stocks, driven by the approval of a domestically developed implantable wireless brain-computer interface system entering the special review process by the National Medical Products Administration of China, marking a significant step in the commercialization of this technology in China [1] Group 1: Stock Performance - Aipeng Medical saw a nearly 12% increase in stock price, with a total market value of 40.03 billion and a year-to-date increase of 80.63% [2] - Century Huatong and Innovative Medical both rose over 7%, with market values of 141.1 billion and 10.5 billion respectively, and year-to-date increases of 269.65% and 198.87% [2] - Botao Biological increased by over 5%, with a market value of 6.62 billion and a year-to-date increase of 95.06% [2] - Xiangyu Medical rose over 4%, with a market value of 8.33 billion and a year-to-date increase of 78.19% [2] - Other notable stocks include Sanbo Brain Science, Saily Medical, Dineike, Taihe Technology, and Chengyi Tong, all showing increases of over 3% [1][2] Group 2: Industry Development - The implantable wireless brain-computer interface system developed by Shanghai Ladder Medical Technology Co., Ltd. is the first invasive brain-computer interface product to enter the "green channel" for innovative medical devices in China, indicating a key advancement from clinical validation to market access in this cutting-edge technology field [1]

Industry Overview - Rehabilitation devices are defined as medical equipment or assistive tools used in rehabilitation to assess, train, and treat patients, helping them improve functionality and recover bodily functions or compensate for deficiencies [1] - The rehabilitation device industry can be categorized into rehabilitation medical aids, rehabilitation therapy equipment, rehabilitation training devices, and assessment instruments [1] Industry Chain Analysis - The upstream of the rehabilitation medical device industry mainly consists of raw materials and software systems, with raw materials being the core element affecting product quality and manufacturing efficiency [2] - The midstream involves the production of rehabilitation assessment instruments, training devices, therapy equipment, and other rehabilitation devices [2] - The downstream consumer segment primarily includes elderly, chronic disease, and disabled groups [2][5] Industry Development History - The Chinese rehabilitation device industry has gone through three stages: initial phase (1980-1989), transformation phase (1990-2011), and rapid growth phase (2012-present), with significant policy support and market expansion in the latter phase [7][8] Policy Background - Recent national policies have promoted high-level standardization and integration of rehabilitation devices with technologies like AI, IoT, and 5G, creating favorable conditions for high-quality industry transformation [10][11] Current Industry Status - The number of registered rehabilitation device products in China has seen explosive growth since 2019, with projections indicating 1,167 registrations by 2024 [14] - The market size for rehabilitation devices in China is expected to reach approximately 21.1 billion yuan in 2024, driven by an aging population and increasing chronic diseases [15] - Rehabilitation aids dominate the market, accounting for 82.15% of the total market size in 2024 [17] - The elderly care segment is projected to account for about 67% of the application structure in 2024 [18] Competitive Landscape - The competitive landscape of the rehabilitation device industry shows a concentration of core manufacturing enterprises in eastern coastal provinces like Jiangsu, Guangdong, and Shandong, while central and western regions focus on raw material supply [21] - The top three companies in the rehabilitation device market by share in 2024 are Kefu Medical, Yuyue Medical, and Xiangyu Medical, with market shares of 6.47%, 6.18%, and 3.51% respectively [24] Future Development Outlook - By 2030, the market size of the rehabilitation device industry is expected to exceed 47 billion yuan, driven by the aging population and increased demand for rehabilitation services [26] - The industry is predicted to grow at a compound annual growth rate (CAGR) of around 14% from 2025 to 2030 [26] Industry Trends - The rehabilitation device industry is experiencing a trend towards smart technology and product diversification, with the integration of AI, IoT, and 3D printing technologies [28] - The aging population and the rise in chronic diseases are expected to sustain the growth of rehabilitation demand, supported by favorable policies and market expansion [28]